Macrogenics (MGNX) Profit After Tax (2012 - 2026)
Macrogenics (MGNX) posted quarterly Profit After Tax of -$36.8 million for Q1 2026, up 10.39% year-over-year from -$33.3 million in Q1 2025, and down 159.78% quarter-over-quarter from -$14.2 million in Q4 2025.
Analysis
Macrogenics (MGNX) Profit After Tax (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Profit After Tax for 15 consecutive years, with -$36.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax rose 10.39% year-over-year to -$36.8 million; the TTM figure through Mar 2026 stood at -$70.4 million (down 26.09% YoY), while the FY2025 annual figure was -$74.6 million, down 11.45% from the prior year.
- Profit After Tax declined to -$36.8 million in Q1 2026 per MGNX's latest filing, from -$14.2 million in the prior quarter.
- Across five years, Profit After Tax topped out at $57.5 million in Q2 2023 and bottomed at -$66.4 million in Q1 2022.
- Historically, Profit After Tax has averaged -$18.1 million across 5 years, with a median of -$36.3 million in 2025.
- On a YoY basis, Profit After Tax climbed as much as 239.14% in 2023 and fell as far as 459.65% in 2023.
- Macrogenics' Profit After Tax stood at $12.8 million in 2022, then tumbled by 459.65% to -$46.0 million in 2023, then jumped by 66.53% to -$15.4 million in 2024, then gained by 8.14% to -$14.2 million in 2025, then tumbled by 159.78% to -$36.8 million in 2026.
- Business Quant data shows MGNX's Profit After Tax at -$36.8 million in Q1 2026, -$14.2 million in Q4 2025, and $16.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Macrogenics | 274.09 Mn | 160.19 Mn | - | -69.64 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -69.64 Mn |
| Mar 31, 2026 | -36.77 Mn |
| Dec 31, 2025 | -14.16 Mn |
| Sep 30, 2025 | 16.83 Mn |
| Jun 30, 2025 | -42.72 Mn |
| Mar 31, 2025 | -41.04 Mn |
| Dec 31, 2024 | -15.42 Mn |
| Sep 30, 2024 | 56.35 Mn |
| Jun 30, 2024 | -55.66 Mn |
| Mar 31, 2024 | -52.19 Mn |
| Dec 31, 2023 | -46.07 Mn |
| Sep 30, 2023 | 17.59 Mn |
| Jun 30, 2023 | 57.47 Mn |
| Mar 31, 2023 | -38.01 Mn |
| Dec 31, 2022 | 12.85 Mn |
| Sep 30, 2022 | -24.81 Mn |
| Jun 30, 2022 | -41.30 Mn |
| Mar 31, 2022 | -66.44 Mn |
| Dec 31, 2021 | -58.08 Mn |
| Sep 30, 2021 | -52.89 Mn |